Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome related Kaposi sarcoma

A decrease in the incidence of human immune deficiency virus-associated Kaposi sarcoma (HIV-KS) and regression of some established HIV-KS lesions is evident after the introduction of highly active anti-retroviral treatment (HAART), and is attributed to generalized immune restoration, to the reconstitution of human herpesvirus (HHV)-8 specific cellular immune responses, and to the decrease in HIV Tat protein and HHV-8 loads following HAART. However, a small subset of HIV-seropositive subjects with a low CD4+ T cell count at the time of introduction of HAART, may develop HIV-KS as immune reconstitution inflammatory syndrome (IRIS) within 8 weeks thereafter

Production of zinc oxide from hazardous waste - Sal Ammoniac Skimming

This article deals with hydrometallurgical treatment with the subsequent precipitation of zinc from hazardous waste Sal- Ammoniac Skimming produced in wet hot-dip galvanizing process. Chemical analysis showed that skimming contained 46.64% Zn. X-ray diffraction analysis identified the Zn(OH)Cl phase (96.36%) and NH4Cl (3.64%) in Sal-Ammoniac Skimming. The skimming was first subjected to leaching in order to extract zinc into the solution containing HCl, followed by precipitation of the zinc. The experiments were performed in a medium of HCl at concentrations of 0.25, 0.5, 1 and 2M. Complete dissolution of zinc was achieved in 0.5M HCl solution, at 40°C, L:S=20, max. 30 min. The apparent activation energy of leaching reaction by hydrochloric acid solution was Ea=5.543 kJ mol-1. Zn precipitation was carried out using Na2CO3 and NaOH. Zinc oxide with a purity of about 99% was obtained directly from the solution of 6M NaOH at a temperature of 60°C – 80°Cat pH 8.8

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration: NCT04126200 (ClinicalTrials.gov)